Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Cash & Current Investments (2016 - 2025)

Corbus Pharmaceuticals Holdings has reported Cash & Current Investments over the past 10 years, most recently at $9.9 million for Q4 2023.

  • For Q4 2023, Cash & Current Investments rose 147.32% year-over-year to $9.9 million; the TTM value through Dec 2023 reached $9.9 million, up 147.32%, while the annual FY2023 figure was $9.9 million, 147.32% up from the prior year.
  • Cash & Current Investments for Q4 2023 was $9.9 million at Corbus Pharmaceuticals Holdings, down from $19.5 million in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $102.6 million in Q2 2021 and troughed at $1.6 million in Q1 2020.
  • A 5-year average of $46.4 million and a median of $40.8 million in 2021 define the central range for Cash & Current Investments.
  • Biggest five-year swings in Cash & Current Investments: surged 4820.51% in 2019 and later crashed 98.24% in 2020.
  • Year by year, Cash & Current Investments stood at $31.7 million in 2019, then skyrocketed by 170.2% to $85.8 million in 2020, then grew by 5.96% to $90.9 million in 2021, then crashed by 95.6% to $4.0 million in 2022, then skyrocketed by 147.32% to $9.9 million in 2023.
  • Business Quant data shows Cash & Current Investments for CRBP at $9.9 million in Q4 2023, $19.5 million in Q3 2023, and $34.8 million in Q2 2023.